PTC Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
PTC Therapeutics, Inc. (PTCT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-30
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.79M, a 2.82% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.76M, a 1.62% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.83M, a 23.78% increase year-over-year.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.00M, a 11.17% increase year-over-year.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $7.47M, a 3.68% decline from fiscal 2024.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $7.75M, a 21.12% decline from fiscal 2023.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $9.83M, a 0.58% decline from fiscal 2022.
- PTC Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $9.88M, a 33.82% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.55M 10-Q · filed 2026-07-30 | $5.38M derived: sum of 3 quarters · filed 2026-07-30 | $7.39M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.76M 10-Q · filed 2026-05-07 | $3.59M derived: sum of 2 quarters · filed 2026-05-07 | $5.59M derived: sum of 3 quarters · filed 2026-05-07 | $7.44M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.83M derived: sum of 2 quarters · filed 2026-02-19 | $5.68M derived: sum of 3 quarters · filed 2026-07-30 | $7.47M 10-K · filed 2026-02-19 |
| 2025-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.85M derived: sum of 2 quarters · filed 2026-07-30 | $5.63M 10-Q · filed 2025-11-04 | $7.12M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.63M 10-Q · filed 2026-07-30 | $5.11M derived: sum of 3 quarters · filed 2026-07-30 | $6.91M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.79M 10-Q · filed 2026-05-07 | $3.27M derived: sum of 2 quarters · filed 2026-05-07 | $5.07M derived: sum of 3 quarters · filed 2026-05-07 | $7.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.28M derived: sum of 2 quarters · filed 2026-02-19 | $5.96M derived: sum of 3 quarters · filed 2026-02-19 | $7.75M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.48M derived: sum of 2 quarters · filed 2025-11-04 | $6.27M 10-Q · filed 2025-11-04 | $7.94M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.47M 10-Q · filed 2025-08-07 | $6.14M derived: sum of 3 quarters · filed 2026-02-19 | $8.63M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $1.79M 10-Q · filed 2025-05-06 | $3.46M derived: sum of 2 quarters · filed 2026-02-19 | $5.95M derived: sum of 3 quarters · filed 2026-02-19 | $8.68M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.15M derived: sum of 2 quarters · filed 2026-02-19 | $6.88M derived: sum of 3 quarters · filed 2026-02-19 | $9.83M 10-K · filed 2026-02-19 |
| 2023-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.21M derived: sum of 2 quarters · filed 2024-11-07 | $8.16M 10-Q · filed 2024-11-07 | $10.54M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.67M 10-Q · filed 2024-08-08 | $8.05M derived: sum of 3 quarters · filed 2025-02-27 | $11.26M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.94M 10-Q · filed 2024-04-25 | $5.32M derived: sum of 2 quarters · filed 2025-02-27 | $8.53M derived: sum of 3 quarters · filed 2025-02-27 | $10.92M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.59M derived: sum of 2 quarters · filed 2025-02-27 | $7.98M derived: sum of 3 quarters · filed 2025-02-27 | $9.88M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $5.60M derived: sum of 2 quarters · filed 2023-10-26 | $7.50M 10-Q · filed 2023-10-26 | $9.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.29M 10-Q · filed 2023-08-03 | $6.17M derived: sum of 3 quarters · filed 2024-02-29 | $8.02M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.91M 10-Q · filed 2023-04-27 | $3.78M derived: sum of 2 quarters · filed 2024-02-29 | $5.63M derived: sum of 3 quarters · filed 2024-02-29 | $7.47M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.72M derived: sum of 2 quarters · filed 2024-02-29 | $5.57M derived: sum of 3 quarters · filed 2024-02-29 | $7.39M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $3.70M derived: sum of 2 quarters · filed 2022-10-27 | $5.52M 10-Q · filed 2022-10-27 | $7.30M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.67M 10-Q · filed 2022-08-04 | $5.46M derived: sum of 3 quarters · filed 2023-02-21 | $7.35M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $1.82M 10-Q · filed 2022-05-03 | $3.61M derived: sum of 2 quarters · filed 2023-02-21 | $5.50M derived: sum of 3 quarters · filed 2023-02-21 | $6.57M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $3.68M derived: sum of 2 quarters · filed 2023-02-21 | $4.75M derived: sum of 3 quarters · filed 2023-02-21 | $6.08M 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $2.96M derived: sum of 2 quarters · filed 2021-10-28 | $4.29M 10-Q · filed 2021-10-28 | $5.56M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $2.40M 10-Q · filed 2021-07-29 | $3.66M derived: sum of 3 quarters · filed 2022-02-22 | |
| 2020-03-31 | $1.33M 10-Q · filed 2021-05-04 | $2.59M derived: sum of 2 quarters · filed 2022-02-22 | ||
| 2019-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $3.71M 10-K · filed 2022-02-22 | ||
| 2019-09-30 | $2.45M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |